الصفحة الرئيسية>>Signaling Pathways>> Neuroscience>> Parkinson>>AUTEN-99

AUTEN-99 (Synonyms: Autophagy Enhancer-99)

رقم الكتالوجGC46897

AUTEN-99 (هيدروبروميد) هو مثبط جديد لـ myotubularin phosphatase Jumpy (ويسمى أيضًا MTMR14).

Products are for research use only. Not for human use. We do not sell to patients.

AUTEN-99 التركيب الكيميائي

Cas No.: 1049780-58-6

الحجم السعر المخزون الكميّة
1 mg
43٫00
متوفر
5 mg
194٫00
متوفر
10 mg
342٫00
متوفر
25 mg
750٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

AUTEN-99 is an inhibitor of the phosphatase myotubularin-related protein 14 (MTMR14/Jumpy).1 It inhibits MTMR14/Jumpy activity in a cell-free assay when used at concentrations of 10 and 100 µM. AUTEN-99 (1 and 10 µM) enhances autophagic flux and increases the levels of LC3B-11 in HeLa cells. It increases survival of mouse primary neurons exposed to hydrogen peroxide as a model of oxidative stress when used at concentrations ranging from 0.5 to 5 µM. AUTEN-99 increases the number of autophagic structures in mouse pancreas, kidney, and liver following oral or intraperitoneal administration. It also induces autophagy in the Drosophila larval fat body and increases the percentage of flies climbing a glass column in a climbing assay in a transgenic model of Parkinson's disease.

1.KovÁcs, T., Billes, V., KomlÓs, M., et al.The small molecule AUTEN-99 (autophagy enhancer-99) prevents the progression of neurodegenerative symptomsSci. Rep.742014(2017)

مراجعات

Review for AUTEN-99

Average Rating: 5 ★★★★★ (Based on Reviews and 34 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for AUTEN-99

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.